杭叉集團(603298.SH)擬發行11.5億元可轉債 初始轉股價23.48元/股
格隆匯3月22日丨杭叉集團(603298.SH)公佈,本次共發行11.5億元可轉債,每張面值為人民幣100元,共計1150萬張,115萬手,按面值發行。可轉債簡稱為“杭叉轉債”,債券代碼為“113622”。初始轉股價格為23.48元/股。
本次可轉債發行原股東優先配售日與網上申購日同為2021年3月25日(T日),網上申購時間為T日9:30~11:30,13:00~15:00。募集資金擬用於年產6萬台新能源叉車建設投資項目、研發中心升級建設項目、集團信息化升級建設項目、營銷網絡及叉車體驗中心建設項目。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.